Intellectual Property
Jul. 18, 2016
Biotech's hopes for answers dashed by the Supreme Court
For much of 2016, many in the biotech industry hoped that the court would revisit the issue — and presumably modify the standard — by granting certiorari in Sequenom Inc. v. Ariosa Diagnostics Inc. By Paul Schuck and Sony Barari
The question of what exactly the biotechnology industry can patent has been the focus of recent Supreme Court law and has ripened into an open industrywide debate. Two landmark Supreme Court decisions ? Mayo Collaborative Servs v. Prometheus Labs. Inc. (2012), and Alice Corp. v. CLS Bank International (2014) ? arguably raised the bar for what is patentable subject matter. Their collective holding...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In